Chemical proteomics application patent granted
The European patent office has granted a patent entitled ?Proteome-wide quantification of small molecule binding to cellular target proteins? to German company, KINAXO Biotechnologies.
The European patent office has granted a patent entitled “Proteome-wide quantification of small molecule binding to cellular target proteins” to German company, KINAXO Biotechnologies.
“The granted patent emphasizes our leadership in providing chemical proteomics solutions for research and development,” says Henrik Daub, KINAXO’s CTO and main inventor of the patent. He says that the company delivers “powerful insights into cellular small molecule target interactions. Such knowledge significantly supports decision-making at various stages of the drug development process.”
The patent covers Cellular Target Profiling, KinAffinity and Epigenetics Target Profiling technologies. According to the company, Cellular Target Profiling enables comprehensive selectivity analysis and prediction of off-target liabilities for compounds with an unclear target spectrum. KinAffinity and Epigenetics Target Profiling are reported to deliver high quality, native selectivity data for kinase inhibitors or epigenetic drugs.
Patent applications in the United States and Japan are pending.
For more information visit www.kinaxo.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
